Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
16. März 2022 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)
20. September 2021 01:00 ET
|
Jeito Capital
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
27. Mai 2021 02:00 ET
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
InnoSkel Launches with €20 Million Series A Financing
14. Dezember 2020 01:00 ET
|
InnoSkel
InnoSkel Launches with €20 Million Series A Financing Proceeds to support development and advancement of innovative gene therapies for patients with rare skeletal diseases Founded and led by...
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
14. Dezember 2020 01:00 ET
|
Jeito Capital
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito’s third international investment in H2 2020, with deep and rapidly...
Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics
14. September 2020 08:00 ET
|
Jeito Capital
Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020Round co-led by Jeito...